A malignant pleural effusion (MPE) is a buildup of fluid in the space between the lung and the chest wall, caused by cancer. It signals advanced disease, and the overall median survival after diagnosis is about 5 months, though this varies significantly depending on the type of cancer involved. MPE affects roughly 150,000 people per year in the United States and is one of the most common complications of advanced cancer.
How Fluid Builds Up
A thin layer of fluid normally sits between the two membranes (the pleura) that line the lungs and the inside of the chest wall. This fluid lets the lungs slide smoothly during breathing. In healthy people, the body constantly produces and reabsorbs this fluid in balance.
Cancer disrupts that balance in two ways. First, tumors can block the lymphatic drainage system that normally removes fluid from the pleural space, anywhere from tiny openings in the chest wall lining to the lymph nodes near the center of the chest. Second, and perhaps more important, the interaction between tumor cells and the body’s own immune and tissue cells triggers a cascade of chemical signals that make blood vessels abnormally leaky. This causes plasma to seep into the pleural space far faster than normal. The protein content in malignant effusions is higher than in normal pleural fluid, confirming that this isn’t simply fluid backing up but actively leaking from damaged vessels.
Interestingly, the volume of fluid doesn’t always match the amount of tumor present. Some patients with minimal pleural tumor develop large effusions, while others with widespread pleural disease accumulate relatively little fluid. This disconnect highlights that it’s the chemical environment the tumor creates, not just its physical presence, that drives fluid accumulation.
Which Cancers Cause It
Lung cancer is the single most common cause, responsible for about 36% of all malignant pleural effusions. Breast cancer accounts for roughly 15%, and lymphoma or leukemia for about 16%. Together, lung and breast cancers make up 50 to 65% of all cases. Ovarian cancer, gastrointestinal cancers, and mesothelioma (a cancer of the pleural lining itself) account for most of the rest. In a small percentage of cases, the primary cancer is never identified.
Symptoms and What They Feel Like
The hallmark symptom is progressive breathlessness. As fluid accumulates, it compresses the lung on the affected side, reducing the space available for breathing. Many people also develop a dry cough and dull chest pain that may worsen with deep breathing. Weight loss and swollen lymph nodes often accompany the effusion, reflecting the underlying cancer.
Some patients with small effusions have no symptoms at all, with the fluid discovered incidentally on imaging done for other reasons. When a doctor examines the chest, the affected side typically sounds dull when tapped (rather than the normal hollow resonance), breath sounds are quieter or absent over the fluid, and the chest may expand unevenly during breathing. Dullness to percussion is one of the most reliable physical signs, with specificity as high as 98%.
How It’s Diagnosed
Chest X-rays often show the effusion first, appearing as a white haze that obscures the lower lung. But confirming that the fluid is malignant requires further steps.
Thoracic ultrasound is particularly useful because it can reveal pleural thickening, nodules on the diaphragm, or irregularities along the chest wall lining. These findings are highly specific for malignancy. CT scans provide a broader picture of the underlying cancer, lymph node involvement, and the extent of pleural disease.
The definitive diagnostic step is thoracentesis: inserting a needle into the pleural space under ultrasound guidance to withdraw fluid for analysis. When a pathologist examines this fluid under a microscope, it correctly identifies cancer cells about 75% of the time. The detection rate varies by cancer type. Breast cancer effusions are identified about 91% of the time, lung cancer about 79%, but mesothelioma only about 33%. For suspected mesothelioma, or when fluid analysis comes back negative but suspicion remains high, a pleural biopsy (taking a small tissue sample from the pleural lining) is the next step.
What Survival Looks Like
Median survival after an MPE diagnosis depends heavily on the underlying cancer. Ovarian cancer carries the longest median survival at around 21 months. Breast cancer follows at about 6 months. Lung cancer and lymphoma both have a median survival of roughly 4 months. These are medians, meaning half of patients live longer, and the range can be wide. Some lung cancer patients in one study survived up to 8 years.
Doctors sometimes use a scoring system called the LENT score to estimate prognosis more precisely. It factors in four variables: a specific enzyme level in the pleural fluid, the patient’s overall physical function, a ratio of immune cells in the blood, and the type of cancer. Patients are grouped into low-risk (scores 0 to 1), moderate-risk (2 to 4), and high-risk (5 to 7) categories. This helps guide decisions about how aggressively to treat the effusion itself.
Treatment Options
Treatment for MPE is palliative, meaning the goal is symptom relief and quality of life rather than cure. There is generally no survival benefit from treating the effusion itself, so doctors aim for the least invasive approach that keeps symptoms controlled.
Observation
Small effusions that aren’t causing symptoms can simply be monitored. Not every effusion needs intervention.
Therapeutic Drainage
For symptomatic patients, the first step is usually a therapeutic thoracentesis, the same needle-based drainage used for diagnosis but with a larger volume of fluid removed. Doctors typically limit removal to about 1.5 liters at a time to reduce the risk of a complication called re-expansion pulmonary edema, which can occur when a collapsed lung re-inflates too quickly. This procedure provides immediate relief and also reveals important information: how well the lung re-expands, how much the breathlessness improves, and how quickly the fluid comes back.
Pleurodesis
If fluid reaccumulates quickly, a more lasting solution is needed. Pleurodesis involves introducing a substance (most commonly talc) into the pleural space to create controlled inflammation that seals the two pleural layers together, eliminating the space where fluid collects. This requires a hospital stay of several days. In clinical trials, talc pleurodesis failed in about 22% of patients within the first few months, requiring additional procedures. Median effusion-related hospital time was 4 days.
Indwelling Pleural Catheter
An indwelling pleural catheter (IPC) is a thin silicone tube tunneled under the skin that stays in place long-term. Patients or their caregivers can drain fluid at home as needed, avoiding repeated hospital visits. In the AMPLE trial, which directly compared IPCs to talc pleurodesis, patients with catheters spent fewer total days in the hospital (median 10 vs. 12 days) and only 4% needed further pleural procedures, compared to 22% in the pleurodesis group. Both approaches provided similar improvements in breathlessness and quality of life. IPCs are also the preferred option for patients with trapped lung, a condition where the lung can’t fully re-expand because tumor or scar tissue encases it.
Pharmacological Comfort Care
For patients in the final days or weeks of life, or those too frail for procedures, medications to manage breathlessness and discomfort become the primary approach. Invasive procedures may no longer be appropriate when the burden of recovery outweighs the benefit, and the focus shifts entirely to comfort.
Trapped Lung
In some patients with advanced pleural disease, the lung becomes “trapped,” meaning it cannot fully inflate even after fluid is drained. This happens when tumor growth or inflammation creates a rigid coating over the lung surface. The result is a persistent space between the lung and chest wall that fills with fluid regardless of drainage. Neither CT nor MRI can reliably diagnose this condition beforehand. Instead, doctors measure how the pressure inside the pleural space changes during drainage. A steep drop in pressure as fluid is removed suggests the lung won’t re-expand.
Trapped lung makes pleurodesis ineffective because the two pleural surfaces can’t come into contact. An indwelling catheter is the most practical option for these patients, allowing regular drainage at home. In select patients who are physically strong enough, surgery to peel the restrictive layer off the lung surface can restore expansion, but this is a significant operation that must be weighed carefully against limited life expectancy.